ClinicalTrials.gg
CompletedNCT02502669Updated Feb 15, 2019

Finasteride Treatment of Severe Nodulocystic Acne

A Phase 2 interventional study of Finasteride 23.5 mg tablets and Finasteride 33.5 mg tablets in NODULOCYSTIC ACNE, sponsored by Elorac, Inc.. Completed at 25 sites in United States. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Elorac, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
162nd of 353
106 · median 78
Started
2015
with 24 others
Phase 2
65 of 373
none open now
Registered
170th of 373
by date

Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 162nd largest by enrollment of the 353 interventional ones that give a count, is one of 25 that started in 2015, is one of 65 in phase 2, and was the 170th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 35 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

Double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of once weekly, high dose oral finasteride compared to placebo for the treatment of severe nodulocystic acne in male subjects.

Read the detailed description

There will be 180 male subjects in this study. The study is composed of a Screening Period of up to 30 days during which inclusion / exclusion criteria will be reviewed, screening laboratory results will be obtained and medication washouts will be done as required. Subjects will complete the sexual function questionnaire and depression scale. A one day Baseline Period (Day 0), during which baseline assessments of acne lesion counts, physical examination and Investigator's Global Assessment Scale will be done. The Baseline Period will be followed by a 12-week randomized double-blind Treatment Period, in which subjects will be randomized into Finasteride 23.5 mg group, 33.5 mg group, or placebo group. During the Treatment Period, subjects will visit the study site Day 14, Day 28, and Day 56 for acne lesion counts and review of diaries, concomitant medications and adverse events. On Day 84 subjects will return to clinic for acne lesion counts and review of diaries, concomitant medications, adverse events and remaining study drug will be counted and collected. A physical exam and vital signs, Investigator Global Assessment, Subject Assessment of Efficacy, depression scale and sexual function questionnaire will be completed before the subject is discharged from the study.

03

Conditions studied

  • NODULOCYSTIC ACNE

Browse trials for

Keywords

  • acne
  • nodulocystic
  • finasteride
  • 5 alpha reductase inhibitor
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject voluntarily agrees to participate in this study and signs an IRB-approved prior to performing any of the screening procedures.
  2. Males 18 years to 35 years of age.
  3. Except for severe nodulocystic acne, subject is in generally good health.
  4. Ten (10) or more nodular lesions (facial and/or truncal).
  5. Weight between 40 and 110 kg.
  6. No significant disease or finding in a physical examination.
  7. No clinically significant abnormal laboratory value.
  8. No clinically significant abnormal vital sign measurement.
  9. Subject is able to swallow pills.
  10. Subject agrees to use a medically acceptable form of barrier-method (e.g. condoms with spermicide or abstinence).
  11. Subject is willing and able to cooperate to the extent required by the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects will be excluded from the study.
  2. Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), pyoderma faciale, sinus tracks.
  3. Subject with a wash out period from Baseline for topical treatment on the skin less than: , antibiotics, antibacterials, antiseptics, retinoids, other anti-inflammatory drugs or other acne treatment (2 weeks); Cosmetic procedures (1 week); Photodynamic therapy and laser therapy for acne (3 months).
  4. Subject with a from Baseline for systemic treatment less than: Corticosteroids, antibiotics (4 weeks), spironolactone (3 months), other systemic acne treatments (6 months), cyproterone acetate (6 months), lithium, anticonvulsants, barbiturates, androgenic and anabolic steroids, testosterone, estrogen, anti-tuberculous drugs, cyclosporine, and azathioprine (6 months), surgical treatment of acne (12 months), finasteride or other 5α-reductase inhibitors (12 months). (Table 2)
  5. Subjects with current or history of prostatic disease including benign prostatic hypertrophy, or surgery on prostate.
  6. Known history or presence of any unstable medical condition(s) which in the opinion of the investigator could pose a risk for the safety of the subject, e.g. diabetes, cardiovascular, liver or kidney disease.
  7. Subjects with any skin disease or other condition that might interfere with the evaluation of nodular acne.
  8. Known history or suspected carcinoma.
  9. Allergy to finasteride or any other ingredients in the study medications.
  10. Subjects with history in past 12 months of active addiction, abuse, misuse and/or dependence on drugs or alcohol.
  11. Use of drug within 90 days prior to Day 1
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Active comparator
    Finasteride 23.5 mg tablets group

    Finasteride 23.5mg tablets and large placebo tablets once per week

    Drug: Finasteride 23.5 mg tablets · Drug: Placebo tablets

  • Active comparator
    Finasteride 33.5 mg tablets group

    Finasteride 33.5 mg tablets and small placebo tablets once per week

    Drug: Finasteride 33.5 mg tablets · Drug: Placebo tablets

  • Placebo comparator
    Placebo group

    Large and small placebo tablets once per week

    Drug: Placebo tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Acne Nodular Lesion Count

    Change from Baseline to week 12 in the total number of nodular lesions

    Time frame: 12 Weeks

Secondary outcomes

  1. Proportion of Subjects who achieve at least a 75% reduction in total number of nodular lesions

    Change from Baseline to week 12 in the total number of nodular lesions

    Time frame: 12 Weeks

  2. Investigator's Global Assessment Scale of Acne Severity

    Change from Baseline to week 12

    Time frame: 12 Weeks

  3. Non-Inferiority (NI) for non-nodulocystic inflammatory lesions

    The NI bound will be larger of 10% reduction or a count of 4 lesions.

    Time frame: 12 Weeks

  4. Change in total number of nodular lesions.

    Change from baseline to weeks 2, 4 and 8.

    Time frame: 2, 4, and 8 weeks

  5. Proportion of subjects with 2 category improvement on Investigator's Global Assessment Scale

    Change from Baseline to week 12

    Time frame: 12 Weeks

07

Study locations

25 sites
  • Omni Dermatology, Inc.
    Phoenix, Arizona 85018, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Dr. Ronald Moy
    Beverly Hills, California 90210, United States
  • Axis Clinical Trials
    Los Angeles, California 90036, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Horizons Clinical Research Center, LLC.
    Denver, Colorado 80220, United States
  • MOORE Clinical Research, Inc.
    Brandon, Florida 33511, United States
  • Advanced Medcial Research Institiute
    Miami Lakes, Florida 33174, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • International Clinical Research
    Sanford, Florida 32771, United States
  • Lenus Research & Medical Group
    Sweetwater, Florida 33172, United States
  • Marietta Dermatology Clinical Research, Inc.
    Marietta, Georgia 30060, United States
  • MedaPhase, Inc.
    Newnan, Georgia 30263, United States
  • Northwest Clinical Trials
    Boise, Idaho 83704, United States
  • Glazer Dermatology
    Buffalo Grove, Illinois 60089, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Summit Dermatology
    Oakbrook Terrace, Illinois 60181, United States
  • Dawes Fretzin Clinical Research Group. LLC
    Indianapolis, Indiana 46256, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Greenwich Village Dermatology
    New York, New York 10012, United States
  • UHCMC Skin Study Center
    Cleveland, Ohio 44106, United States
  • Paddington Testing Co., Inc.
    Philadelphia, Pennsylvania 19103, United States
  • Invocare Clinical Research Center
    West Columbia, South Carolina 29169, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2015
First posted
Jul 20, 2015
Start
Jul 2015
Primary completionActual
Jun 6, 2017
CompletionActual
Jun 6, 2017
Results delay requested
Feb 7, 2019
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02502669
Lead sponsor
Elorac, Inc.
Responsible party
Sponsor
First posted
Jul 20, 2015
Start date
Jul 2015
Primary completion
Jun 6, 2017
Completion
Jun 6, 2017
Last update
Feb 15, 2019

Study contacts

Scott B. Phillips, MD
study director · Elorac, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finasteride

Start the discussion